Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Inositol,Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Details : Inofolic is a natural health product, combining myo-inositol and folic acid in a unique soft-gel capsule for women living with PCOS. Inofolic® helped 70% of women with PCOSii to regulate their menstrual cycles throughout the 16-week study period.
Product Name : Inofolic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Inositol,Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Folic Acid,Iron
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Cipla
Deal Size : $12.3 million
Deal Type : Acquisition
Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore.
Details : Cipla has acquired the four brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in the women's health segment, Cipla said in a filing to the BSE.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
July 02, 2020
Lead Product(s) : Folic Acid,Iron
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Cipla
Deal Size : $12.3 million
Deal Type : Acquisition
Lead Product(s) : Folic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Second Affiliated Hospital, Nanchang University | Shenzhen Evergreen Medical Institute | Nanfang Hospital, Southern Medical University | Peking University First Hospital | The First People's Hospital of Lianyungang | People's Hospital of Rongcheng | Anqin
Deal Size : Inapplicable
Deal Type : Inapplicable
H-Type Hypertension Precision Medicine Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 21, 2018
Lead Product(s) : Folic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Second Affiliated Hospital, Nanchang University | Shenzhen Evergreen Medical Institute | Nanfang Hospital, Southern Medical University | Peking University First Hospital | The First People's Hospital of Lianyungang | People's Hospital of Rongcheng | Anqin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Folic Acid
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Genomind
Deal Size : Inapplicable
Deal Type : Inapplicable
McLean and Genomind Prospective Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2017
Lead Product(s) : Folic Acid
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Genomind
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Duchesnay
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimizing Periconceptional and Prenatal Folic Acid Supplementation
Details : Undisclosed
Product Name : PregVit
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 25, 2014
Lead Product(s) : Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Duchesnay
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Duchesnay
Deal Size : Inapplicable
Deal Type : Inapplicable
Improving Multivitamin Supplementation to Pregnant Women
Details : Undisclosed
Product Name : PregVit
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 24, 2014
Lead Product(s) : Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Duchesnay
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Folic Acid
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Iron/Folic Acid vs Folic Acid Supplements During Pregnancy on Maternal and Child Health
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 20, 2014
Lead Product(s) : Folic Acid
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Folic Acid
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 29, 2011
Lead Product(s) : Folic Acid
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable